VRTX

Vertex owns the cystic fibrosis market with its triple-combination therapy Trikafta, treating 90% of CF patients and generating $9.9 billion in 2023 revenue. The company's expertise in rare disease drug development creates massive barriers to entry, with Trikafta alone treating a patient population that competitors abandoned as too small and scientifically challenging. Vertex is advancing VX-548, a non-opioid pain medication targeting Nav1.8 channels, into Phase 3 trials for acute pain with results expected in 2025. Trading at 20x forward earnings despite 22.5% ROE, the stock offers exposure to a franchise that prints cash while building the next generation of breakthrough therapies. Management expects Trikafta revenue to plateau around $10-11 billion, but the pain program alone addresses a $15 billion addressable market.